Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II  by Tardiff, Barbara E. et al.
JACC Fe1~'~y I~9.5 
Association of  Pre-lntervent!on Aotivatcd Clotting 
. . . .  ]_trees (AGg") and Clinical Outcomes Following 
Percutaneous Coronary Revasculaflzation: Results 
From the IMPACT-II Trial 
Frank V. Agulrre, James J. Ferguson, James C. Blankanship, Karen 
S. Pleper, Marc Taylor, Robert A. Harrington, MIchele Rund, Eugene 
A, Caracololo, Thomas J. Dnnot, ue, Robert M. Caliri, A. Michael Uncoff, 
James E, Tcheng, Eric J. Topoi. for the IMPACT-II Investigators. St. Louis 
Univet~ity, St. Louis, MO 
Pdor studies show high rates of adverse clinical outcomes with low prosedural 
ACTs during coronary revascularization, We evaluated ACTs and clinical 
OUtcomes of 3296/4010 (8P/o) pts enrolled tn the IMPACT.II •al In whom 
pro-intervention ACTS were available. All pts received aspirin and weight- 
edjusted IV hepadn to achieve a pre-interventlan ACT of 300-350 secs. Pie 
were randomized to receive placebo (n : 1t04) or integrelin (n ,= 2192). 
Pdmaw endpoint was the 30.day combined (ncldanca of death, M1, or urgent 
revasculadzation. Pra-lnten~ntion median ACTs were 33I vs 324 sees in pta 
with and without a primery endpoint. PdmaW ~pclnts w6re more frequent 
Pro-intervention Primary Endpotnt, . 
ACT Terlile (~)  Placebo Imegrelin 
< 30~ 9% 9% 
303-.352 12% lO% 
> 353 15% 10% 
Conclusion: IMPACT-U pre-interventional ACT data demonstrate similar 
rates of adverse outcomes in integralin-treated pts regardless of ACT, but 
appeared to p~radoxically occur mere frequently, over a narrow but increas- 
Ing ACT range in ~.%¢bo pLY. ~'~,,i: often ~,?.ppears to be attenuated by GP 
Ilb/ll;a antagonism. Those unexpected results raise the question as to mech- 
anism and accuracy of recommended ACT thresholds based on empiric 
studies. 
Pharmscoiogl¢ Modulation of the Collateral 
Vascular Resistance in AcUte and Chronio Coronary 
O~lus ion  Assessed by  Intraooronary Blood Row 
Velocity Analysis 
Jan J. Piek, Rob A.M. van Lisbergen, Karet Th. Koch, Ran J.G. Peters, 
George K. David. Academic Medical Center, Amsterdam, the Netherlands 
Aim of the study: To assess the direct erie= of vasodiisfurs on coronary 
collateral vascular esistance in acute and chronic coronary occlusion. 
Methods: Patients with 1-vessel disease, antegrade flow and presence of 
collateral vessels during balloon coronary occlusion (BCO, n = 25, group I) 
were compared with patients with a collateralized 1-vessel chronic coronary 
occlusion (n = 18, group II). Presence of collateral vessels during BCO was 
determined by anglography of the donor artery (grade 2--3 according to 
Rentrop's dassitication). Collateral flow (Vcall) was assessed in the recipient 
coronary artery during BCO by the distal maximal diastolic blood fl0w velocity 
(> 5 cm/esc) with the use of a 0.014" Doppler tipped guidewtre. Adenosine 
(12-18/~g) and nitroglycerin (0.1-0.2 mr) were injected separately as a 
bolus in the donor coronary artery during subsequent BCO's to assess the 
effect on Vccll. Aortic pressure (Pea) end coronary wedge pressure (Pw) 
were used to calCulate the relative collateral vascular esistance: Rccll = Pea 
- PwNcclt (mmHg/cm/sec). 
Results: Collateral flow was detected In 14 of the 25 patients (56%) in 
group I and in all patients in group II. 
Baseltne Adenosine Nitroglycerin 
Group Ir ~ VC0il 15.8 4- 9IS 17.14"10 17.~ 4' 11 
(n'* 14) PW/Pao 0.384-0.13 0.384-0.1 0,41 4-0.15 
Rcotl 5,4 4- 3.9 5,3 4. 4.2 5.4 4- 5.3 
Group, Vcoll 18.44-7.7 24.3± 10t 24.94-10 t 
(n,~ 18) Pw/Pao 0.464-0.12 0.424-0.08 0.46~ 0.12 
RcOll 3.4 4- 1.6 2.7 4-1.4" 2.5 4-1.3 t
*p < 0,05; tp < 0 005. compared to baseline values by paired t-test, 
Conclusion: The collateral vascular resistance In chronic coronary ocolu, 
slon ?,,an be reduced, in contrast o the setting of acute coronary occlusion, 
by vesodilators of the arterioler esistance vessels as well as by vasndiistors 
that exert heir effect on the conductance arteries. 
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/de ntiflc~t, ion of.Ultra Low-Risk Patients Following 
~ lmary  Angloplasty for Acute Myocardial Infarction 
Theodore Schreiber, Dominic Marsatese, John Griffin, Bryan Donohue, 
A. Sampoclesi, Constantine Constantinl, Gregg Stone, Denise E. Jones, 
Dabrs Sachs, Denise Mason, Thomas W~arton, Donald Rothbaum, 
Bruce Brodie, William W. O'Neill, Cindy L. Grines. Wil/iarn Beaumont 
Hospital, Royal Oak, MI 
Hesfth care reform mandates cost containment, therefore hospitals are being 
scrutinized to discharge patients early. In the PAMI-2 study, the performance 
of acute catherization and primary PTCA has been shown to achieve high 
rates of reporfuslon and permit the triage of tow-risk patients (age < 70, 
LVEF > 45%, 1-.2 vessel CAD) to be admitted to a telemetry unit and early 
discharge at 3 days. To determine whether this paradigm further permits e- 
ts=ion of an "ultra low" risk (ULR) subgroup otentially eligible for discharge 
at 48 hours, a cohort of tow-risk PAMI-2 patients with TIMI-3 tiow, residual 
stenosts < 30%, age < 60, single vessel disease with no thrombus/dissection 
after pdrrary PTCA were evaJuated, 
E~lpoint ULR (N = 150) .... Low Risk (N - 3o9) p 
Death 0.0% 0.65% 0.32 
Rslnfarction 0.67% 3,88% 0.05 
Reocolusion 0,67% 4.21% 0.03 
CVA/TIA 0 1,09% 0.11 
CHF 0,67% 3.88% 0.05 
Combined 1.S3% 8,74% 0.002 
The combination of clinical and cath descriptors and excellent angiogrsphi¢; 
results following primary PTCA permits identification of a subgroup of AMI 
patients with an extremely benign course, potentially eligible for dissharge at 
48 hours. This finding has important cost implications. 
• Post-Intervention Cardiac Enzyme Elevations: 
Prognostic Slgrdflcance in IMPACT Ii 
Barbara E. Tardiri, Robert M. Calift, James E. Tcheng, A. Michael Lincoff, 
KfistJna N. Sign~n, Robert A. Herrington, Kenneth W. Mahatley, 
Paul Teirstein, James Heinsimer, Eric J. Topoi, for the IMPACT-11 
Investigators. Duke University, Durham. NC 
The significance of CKMB elevations after coronary intervention was exam- 
ined in the IMPACT II tflal evaluating intsgrslin in PTCA. This analysis in- 
cluded the 2432 patients with available CKMB levels in the post-intervention 
period (4-20 hr). 1795 patients (74%) had no elevation; 328 (14%) hnd 
CKMB 1-3 times the institutional upper limit of normal; increases were 3- 
5x In 83 (4%), 5--10x in 92 (4%) and > 10x in 123 (5%) patients. Clinical 
outcomes, including subsequent myocardial infarctions (MI), were stratified 
by post.procedure CKMB (multiple of normal). CABG and PTCA include 
urgentJeme,gancy procedures only, Patients with elevated CKMB after suc- 
cessful revascularizations (composite of death, MI, procedures-It.5%) had 
fewer events than patients with unsuccessful interventions (29.8%) but more 
than patients with normal post-procedural CKMB (3.0%). 
30-i mB]O-] IBI-3 m3,$ m5-10 D>t0 
20, 
0.  ! __m-I : 1 - 1 l 
Composite Death MI CABG PTCA 
Conclusion: Elevations in CKMB fullowir,~, even successful psrcutanecus 
interventions may identify a pepulatio,9 at high risk for future events. The 
degree of dsk is proportional to the dee in CKMB. 
Predlctom of Abrupt Closure and Consequences of 
Emergency Endpolnts In the IMPACT II Trial 
Brace A. Bergelson, Charles J. Davidson, Gail Harley, Russell Ivanhoe, 
James J. Ferguson, Barbara E. Tardiff, Kenneth W. Mahariey, A. 
Michael Uncoff, James T. Tcheng, Robert M. Caliri, Edc J. ToFol, for the 
IMPACT II Investigators. Northwestern Univ., Ch~,  IL 
To evaluate the predictors of abrupt vessel closure (AC) in patients treated 
with the GP Ilb/Ita antagonist, Integ~in, asubgroup analysis was performed 
within the IMPACT II trial. Compared with placebo (n = 1328), Integrelin (n = 
2682) reduced the incidence of AC from 5.0% to 3.1% {p = 0.004) and need 
fur emergent CABG from 2.8"/o to 1.8% (p = 0.034). Signif'P.ant multivariate 
predictors of AC after adjusting for treatment were: 
